Thuy Tran

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

2005 Apotekarexamen, Uppsala universitet
2008 Masterexamen i Medicinsk radionuklidteknik, Uppsala universitet
2009 Doktorsexamen i Biomedicinsk strålningsvetenskap, Uppsala universitet
2016 Docent i experimentell onkologi, Lunds universitet

Forskningsbeskrivning

Min grupp utvecklar radioaktiva läkemedel som kan användas för diagnostik och terapi av olika cancertyper. Vi bedriver ett unikt utvecklingsarbete inom cyklotronproducerade radiometaller. Många av dessa radiometaller är långlivade och kan användas för märkning av substanser, med en relativt långsam kinetik som t.ex. antikroppar, för molekylär avbildning med PET. Mer om vår forskning, läs gärna på den engelska sidan Translational Theranostics Group

Artiklar

Article: NUKLEARMEDIZIN-NUCLEAR MEDICINE. 2025;64(02):163-169
Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model
Orbom A; Evans-Axelsson S; Jansson B; Timmermand OV; Tran TA; Bjartell A; Strand S-E
Article: EJNMMI RESEARCH. 2025;15(1):12
First-in-human experience with GRPR antagonist [⁶⁸Ga]Ga-NOTA-PEG₂-RM26 in prostate and breast cancer patients using PET/CT
Bjareback A; Jonmarker O; Tzortzakakis A; Jussing E; Li C; Altena R; Hindorf C; Orlova A; Axelsson R; Tran TA
Article: EJNMMI RADIOPHARMACY AND CHEMISTRY. 2025;10(1):4
Rapid fabrication and dissolution of pressed ⁵⁸Ni/Mg matrix targets for ⁵⁵Co production
Siikanen J; Milton S; Bratteby K; Lin W; Engle JW; Jussing E; Tran TA
Article: JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY. 2024;52(3):221-228
Acquisition Duration Optimization Using Visual Grading Regression in [⁶⁸Ga]FAPI-46 PET Imaging of Oncologic Patients
Nilsson T; Rasinski P; Smedby O; af Buren S; Sparrelid E; Lohr JM; Tran TA; Blomgren A; Tzortzakakis A; Axelsson R; Holstensson M
Journal article: ANNALS OF ONCOLOGY. 2024;35:s402-s403
Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study
Altena R; Tzortzakakis A; Blomgren A; Jussing E; Ekman S; Tran T; Axelsson R; Bergh J
Article: EJNMMI RADIOPHARMACY AND CHEMISTRY. 2024;9(1):35
GMP production of [18F]FE-PE2I on a TRACERLab FX2 N synthesis module, a radiotracer for in vivo PET imaging of the dopamine transport.
Ferrat M; Moein MM; Cananau C; Tegnebratt T; Saliba P; Norman F; Steiger C; Bratteby K; Samén E; Dahl K; Tran TA
Article: NUCLEAR MEDICINE COMMUNICATIONS. 2024;45(5):389-395
[¹⁸F]-PSMA-1007 PET imaging optimization and inter-rater reliability - a comparison of three different reconstructions read by four radiologists
Jonmarker O; Nilsson T; Axelsson R; Ericson LH; Tran TA; Tzortzakakis A; Savitcheva I; Holstensson M
Article: JOURNAL OF NUCLEAR MEDICINE. 2024;65(5):700-707
Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [ 68 Ga]Ga-ABY-025: Results from a Pilot Study
Altena R; af Buren S; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
Journal article: EJNMMI RADIOPHARMACY AND CHEMISTRY. 2024;9(1):35
GMP production of [¹⁸F]FE-PE2I on a TRACERLab FX2 N synthesis module, a radiotracer for in vivo PET imaging of the dopamine transport
Ferrat M; Moein MM; Cananau C; Tegnebratt T; Saliba P; Norman F; Steiger C; Bratteby K; Samen E; Dahl K; Tran TA
Article: EJNMMI RADIOPHARMACY AND CHEMISTRY. 2023;8(1):42
Microfluidic-based production of [⁶⁸Ga]Ga-FAPI-46 and [⁶⁸Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer
Mallapura H; Ovdiichuk O; Jussing E; Thuy TA; Piatkowski C; Tanguy L; Collet-Defossez C; Langstrom B; Halldin C; Nag S
Article: EJNMMI RADIOPHARMACY AND CHEMISTRY. 2023;8(1):41
Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [⁶⁸Ga]Ga-ABY-025 tracer
Jussing E; Ferrat M; Moein MM; Alfredeen H; Tegnebratt T; Bratteby K; Samen E; Feldwisch J; Altena R; Axelsson R; Tran TA
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108801
P-343 Targeting brain tumours with radiolabelled chlorotoxin, a scorpion venom peptide
Zafar I; Li K; Zammit J; Palm KP; Davydova M; Varshney M; Lu L; Tran T; Bergstrom T; Swartling FJ; Lewis J; Holmin S; Goos J
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108721
P-258 First time evaluation of 45Ti for radiolabeling of NOTA and DOTA chelators
Milton S; Jussing E; Bratteby K; Ferrat M; Samen E; Tran T; Siikanen J
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108673
P-208 In vivo evaluation and optimization of [89Zr]Zr-DFO-NCS and [89Zr] Zr-(oxinate)4 for cell tracking
Friberger I; Tran T; Lu L; Milton S; Samen E; Goos J; Carlsten M; Holmin S
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108800
P-342 Cancer theranostics using radiolabelled PARP inhibitors
Ferrat M; Mercier G; Milton S; Mohammad M; Samen E; Tran T
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108455
O-59 Preclinical evaluation of [89Zr]Zr-DFO*-sacituzumab, a PET tracer for imaging of whole body TROP-2 expression as a potential selection tool for treatment with TROP-2 antibody drug conjugates (ADC)
Bratteby K; Smertinaite L; Omer S; Lu L; Milton S; Jussing E; Siikanen J; Samen E; Axelsson R; Foukakis T; Altena R; Tran T
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108529
P-057 Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer
Jussing E; Alfredéen H; Moein MM; Tegnebratt T; Bratteby K; Samen E; Altena R; Axelsson R; Tran T
Journal article: ANNALS OF ONCOLOGY. 2023;34:s384
Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer
af Buren S; Axelsson R; Jussing E; Karlsson M; Blomgren A; Brun N; Frejd FY; Tran TA; Altena R
Article: EJNMMI RESEARCH. 2023;13(1):73
Comparative in vivo biodistribution of cells labelled with [⁸⁹Zr]Zr-(oxinate)₄ or [⁸⁹Zr]Zr-DFO-NCS using PET
Friberger I; Nilsson JNN; Lu L; Siikanen J; Ardenfors O; Milton S; Samen E; Goos JACM; Carlsten M; Holmin S; Tran TAA
Article: JOURNAL OF NUCLEAR MEDICINE. 2023;64(8):1232-1237
Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial
Rasinski P; af Buren S; Holstensson M; Nilsson T; Loizou L; Tran TA; Sparrelid E; Lohr JM; Axelsson R
Article: CELL TRANSPLANTATION. 2023;32:9636897231212780
Phenotyping of Macrophages After Radiolabeling and Safety of Intra-arterial Transplantation Assessed by SPECT/CT and MRI
Friberger I; Gontu V; Harris RA; Tran TA; Lundberg J; Holmin S
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:s216-s217
P-307 Comparative in vivo biodistribution and dosimetry in non-human primate of the fibroblast activation protein radiotracers [68Ga]Ga-FAPI-04, [68Ga]Ga-FAPI-46 and [18F]FAPI-74
Tran T; Bolin M; Dahl K; Johnstrom P; Mitran B; Siikanen J; Schou M
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:s132-s133
P-153 High yield GMP production of [18F]FE-PE2I, a radiotracer for in vivo PET imaging the dopamine transporter
Moein MM; Dahl K; Meijer E; Ferrat M; Tegnebratt T; Saliba P; Norman F; Samen E; Steiger C; Savitcheva I; Tran T
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:s122-s123
P-133 Automated radiolabeling of [68Ga]Ga-DOTATOC using the iMiDEV™ automated microfluidic radiosynthesizer
Chandrashekara HK; Tran T; Jussing E; Tanguy L; Långström B; Le Meunier L; Halldin C; Nag S
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:s197-s198
P-271 Preparation and cGMP-compliant production of the bombesin analogue [68Ga]Ga-NOTA-RM26 for first-in-human clinical study of gastrin-releasing peptide receptor expression in prostate cancer
Jussing E; Moein MM; Tegnebratt T; Semetaite V; Liepins E; Tzortzakakis A; Axelsson R; Orlova A; Tran T
Article: PHARMACEUTICALS. 2021;14(12):1251
Humanization, Radiolabeling and Biodistribution Studies of an IgG₁-Type Antibody Targeting Uncomplexed PSA for Theranostic Applications
Strand J; Sjostrom K; Lamminmaki UJ; Vilhelmsson Timmermand O; Strand S-E; Tran TA
Article: MOLECULAR IMAGING AND BIOLOGY. 2021;23(6):952-962
Optimisation of the Synthesis and Cell Labelling Conditions for [⁸⁹Zr]Zr-oxine and [⁸⁹Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samen E; Carlsten M; Holmin S; Tran TA
Article: APPLIED RADIATION AND ISOTOPES. 2021;176:109825
Cyclotron-produced ⁶⁸Ga from enriched ⁶⁸Zn foils
Siikanen J; Jussing E; Milton S; Steiger C; Ulin J; Jonsson C; Samen E; Tran TA
Article: BIOMOLECULES. 2021;11(8):1118
Clinically Applicable Cyclotron-Produced Gallium-68 Gives High-Yield Radiolabeling of DOTA-Based Tracers
Jussing E; Milton S; Samen E; Moein MM; Bylund L; Axelsson R; Siikanen J; Tran TA
Article: CANCERS. 2021;13(14):3469
A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen
Timmermand OV; Orbom A; Altai M; Zedan W; Holmqvist B; Safi M; Tran TA; Strand S-E; Strand J
Article: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2021;64(8):346-352
Fully automated production of the fibroblast activation protein radiotracer [¹⁸F]FAPI-74
Dahl K; Jussing E; Bylund L; Moein MM; Samen E; Tran T
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2021;41(3):617-629
The cellular basis of increased PET hypoxia tracer uptake in focal cerebral ischemia with comparison between [¹⁸F]FMISO and [⁶⁴Cu]CuATSM
Little PV; Arnberg F; Jussing E; Lu L; Jensen AI; Mitsios N; Mulder J; Tran TA; Holmin S
Article: INTERNATIONAL JOURNAL OF NANOMEDICINE. 2020;15:6137-6152
ORIGINAL RESEARCH Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe
Ahmed M; Tegnebratt T; Tran TA; Damberg P; Gistera A; Tarnawski L; Bone D; Hedin U; Eriksson P; Holmin S; Gustafsson B; Caidahl K
Article: ANTIOXIDANTS & REDOX SIGNALING. 2019;30(14):1746-1759
Protection of Kidney Function with Human Antioxidation Protein α₁-Microglobulin in a Mouse ¹⁷⁷Lu-DOTATATE Radiation Therapy Model
Kristiansson A; Ahlstedt J; Holmqvist B; Brinte A; Tran TA; Forssell-Aronsson E; Strand S-E; Gram M; Akerstrom B
Article: THERANOSTICS. 2019;9(8):2129-2142
Preclinical efficacy of hK2 targeted [¹⁷⁷Lu]hu11B6 for prostate cancer theranostics
Timmermand OV; Elgqvist J; Beattie KA; Orbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand S-E
Journal article: FREE RADICAL BIOLOGY AND MEDICINE. 2018;120:s99-s100
Protection of kidney function with human antioxidation protein α1-microglobulin (A1M) in a mouse 177Lu-DOTATATE radiation therapy model
Kristiansson A; Ahlstedt J; Holmqvist B; Brinte A; Tran TA; Forssell-Aronsson E; Strand S-E; Gram M; Akerstrom B
Article: PHYSICS IN MEDICINE AND BIOLOGY. 2017;63(1):015026
¹³⁵La as an Auger-electron emitter for targeted internal radiotherapy
Fonslet J; Lee BQ; Tran TA; Siragusa M; Jensen M; Kibedi T; Stuchbery AE; Severin GW
Article: SCIENTIFIC REPORTS. 2017;7(1):4824
Combined Magnetomotive ultrasound, PET/CT, and MR imaging of ⁶⁸Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo
Evertsson M; Kjellman P; Cinthio M; Andersson R; Tran TA; Zandt R; Grafstrom G; Toftevall H; Fredriksson S; Ingvar C; Strand S-E; Jansson T
Article: EJNMMI RESEARCH. 2016;6(1):27
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2
Timmermand OV; Larsson E; Ulmert D; Tran TA; Strand SE
Article: NUCLEAR MEDICINE AND BIOLOGY. 2015;42(4):375-380
Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution
Vilhelmsson-Timmermand O; Santos E; Thorek DLJ; Evans-Axelsson S; Bjartell A; Lilja H; Larson SM; Strand S-E; Tran TA; Ulmert D
Article: JOURNAL OF NUCLEAR MEDICINE. 2015;56(3):444-449
Intratherapeutic Biokinetic Measurements, Dosimetry Parameter Estimates, and Monitoring of Treatment Efficacy Using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy
Timmermand OV; Tran TA; Strand S-E; Axelsson J
Article: AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2015;5(4):333-347
Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys.
Ahlstedt J; Tran TA; Strand F; Holmqvist B; Strand S-E; Gram M; Åkerström B
Article: EJNMMI RESEARCH. 2014;4(1):51
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a ¹¹¹In-radiolabelled monoclonal antibody, 11B6
Timmermand OV; Ulmert D; Evans-Axelsson S; Pettersson K; Bjartell A; Lilja H; Strand S-E; Tran TA
Article: APPLIED RADIATION AND ISOTOPES. 2014;94:294-301
A solid target system with remote handling of irradiated targets for PET cyclotrons
Siikanen J; Tran TA; Olsson TG; Strand S-E; Sandell A
Article: AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;4(4):311-323
Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer.
Evans-Axelsson S; Vilhelmsson Timmermand O; Welinder C; Borrebaeck CA; Strand S-E; Tran TA; Jansson B; Bjartell A
Article: AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2013;4(1):60-69
(68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes.
Madru R; Tran TA; Axelsson J; Ingvar C; Bibic A; Ståhlberg F; Knutsson L; Strand S-E
Article: JOURNAL OF NUCLEAR MEDICINE. 2012;53(6):953-960
Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
Tolmachev V; Tran TA; Rosik D; Sjoberg A; Abrahmsen L; Orlova A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2011;39(2):353-359
Effects of affinity on binding of HER2-targeting Affibody molecules: Model experiments in breast cancer spheroids
Qvarnstrom OF; Simonsson M; Carlsson J; Tran TA
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2010;37(2):260-269
¹⁸⁶Re-maSGS-Z_HER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours
Orlova A; Tran TA; Ekblad T; Karlstrom AE; Tolmachev V
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2009;36(11):1864-1873
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging
Tran TA; Rosik D; Abrahmsen L; Sandstrom M; Sjoberg A; Wallberg H; Ahlgren S; Orlova A; Tolmachev V
Article: JOURNAL OF NUCLEAR MEDICINE. 2009;50(5):781-789
Targeting of HER2-Expressing Tumors with a Site-Specifically ^99mTc-Labeled Recombinant Affibody Molecule, Z_HER2:2395, with C-Terminally Engineered Cysteine
Ahlgren S; Wallberg H; Tran TA; Widstrom C; Hjertman M; Abrahmsen L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
Article: BIOCONJUGATE CHEMISTRY. 2008;19(12):2568-2576
Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of ^99mTc-Labeled Anti-HER2 Affibody Molecules
Tran TA; Ekblad T; Orlova A; Sandstrom M; Feldwisch J; Wennborg A; Abrahmsen L; Tolmachev V; Karlstrom AE
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2008;35(12):2245-2255
Development and preclinical characterisation of ^99mTc-labelled Affibody molecules with reduced renal uptake
Ekblad T; Tran T; Orlova A; Widstrom C; Feldwisch J; Abrahmsen L; Wennborg A; Karlstrom AE; Tolmachev V
Article: BIOCONJUGATE CHEMISTRY. 2007;18(6):1956-1964
^99mTc-maEEE-Z_HER2:342, an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors
Tran T; Engfeldt T; Orlova A; Sandstroem M; Feldwisch J; Abrahmsen L; Wennborg A; Tolmachev V; Karlstroem AE
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2007;34(11):1843-1853
^99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule
Engfeldt T; Tran T; Orlova A; Widstroem C; Feldwisch J; Abrahmsen L; Wennborg A; Karlstroem AE; Tolmachev V
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2007;20(3):397-404
Pre-clinical evaluation of [¹¹¹In]-benzyl-DOTA-Z_HER2:3429 a potential agent for imaging of HER2 expression in malignant tumors
Orlova A; Tran T; Widstrom C; Engfeldt T; Karlstrom AE; Tolmachev V
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2007;34(5):722-733
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the ^99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence
Engfeldt T; Orlova A; Tran T; Bruskin A; Widstroem C; Karlstroem AE; Tolmachev V
Article: BIOCONJUGATE CHEMISTRY. 2007;18(2):549-558
In vivo evaluation of cysteine-based chelators for attachment of ^99mTc to tumor-targeting affibody molecules
Tran T; Engfeldt T; Orlova A; Widstrom C; Bruskin A; Tolmachev V; Karlstrom AE
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2007;19(3):485-493
Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand
Tran T; Orlova A; Sivaev I; Sandstrom M; Tolmachev V
Article: CANCER RESEARCH. 2007;67(5):2178-2186
Synthetic affibody molecules:: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors
Orlova A; Tolmachev V; Pehrson R; Lindborg M; Tran T; Sandstrom M; Nilsson FY; Wennborg A; Abrahmsen L; Feldwisch J
Visa fler

Alla övriga publikationer

Letter: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2025;:3073-3074
Reply to Vaz et al., Editorial Commentary: Should "Heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?
Altena R; Tran TA; Tzortzakakis A
Preprint: BIORXIV. 2025
Radionuclide selection influences imaging outcomes in immunoPET with a brain-penetrant anti-Aβ antibody
van den Broek SL; Bratteby K; Aguilar X; Tran TA; Syvänen S; Sehlin D
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2024;51:S39-S40
GMP development of the [177Lu]Lu-AKIR001 for clinical translation in first-in-human studies of CD44v6 expressing cancer patients
Bratteby K; Jussing E; Ferrat M; Bylund L; Tegenbratt T; Garousi J; Frejd F; Furebring T; Frank P; Altena R; Mortensen A; Nestor M; Tran TTA
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2024;51:S823-S824
Estrogen-positive metastatic breast cancer examined with [⁶⁸Ga]Ga-NOTA-PEG₂-RM26 PET/CT - First in Human experience
Tzortzakakis A; Bjareback A; Hindorf C; Buren SA; Jussing E; Tolmachev V; Varasteh Z; Moein M; Tran T; Axelsson R; Orlova A; Altena R
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2024;51:S803
Dosimetry from the first-in-human study on [⁶⁸Ga]GaNOTA-PEG 2-RM26-A GRPR antagonist
Bjareback A; Tzortzakakis A; Estenberg U; Axelsson R; Jonmarker O; Altena R; Li C; Moein M; Orlova A; Tran TA; Hindorf C
Letter: JOURNAL OF NUCLEAR MEDICINE. 2023;64(11):1841
HER2-Low Breast Cancer Can Be Visualized by HER2 PET
Altena R; af Buren S; Tran T; Axelsson R
Preprint: RESEARCH SQUARE. 2023
Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer
Jussing E; Ferrat M; Moein MM; Alfredéen H; Tegnebratt T; Bratteby K; Samén E; Feldwisch J; Altena R; Axelsson R; Tran TA
Review: EJNMMI RESEARCH. 2023;13(1):43
Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications
Altena R; Tzortzakakis A; Buren SA; Tran TA; Frejd FY; Bergh J; Axelsson R
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:S46
Preclinical evaluation of [⁸⁹Zr]Zr-DFO*-sacituzumab, a PET tracer for imaging of whole body TROP-2 expression as a potential selection tool for treatment with TROP-2 antibody drug conjugates (ADC)
Bratteby K; Smertinaite L; Omer S; Lu L; Milton S; Jussing E; Siikanen J; Samen E; Axelsson R; Foukakis T; Altena R; Tran T
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:S301
Targeting brain tumours with radiolabelled chlorotoxin, a scorpion venom peptide
Zafar I; Li K; Zammit J; Palm KP; Davydova M; Varshney M; Lu L; Tran T; Bergstrom T; Swartling FJ; Lewis J; Holmin S; Goos J
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2023;50(SUPPL 1):S493
A dose optimization study using Visual Grading Regression in [68Ga]-FAPI-46 PET imaging of patients with pancreatic lesions
Nilsson T; Rasinski P; af Buren S; Smedby O; Blomgren A; Lohr M; Sparrelid E; Tran T; Axelsson R; Holstensson M
Editorial comment: CLINICAL NUCLEAR MEDICINE. 2022;47(7):644-645
A ⁶⁸Ga-FAPI-46 PET/CT Imaging Pitfall in Assessing Residual Gastric Cancer Early After Chemotherapy
af Buren S; Tran TA; Klevebro F; Holstensson M; Axelsson R
Corrigendum: MOLECULAR IMAGING AND BIOLOGY. 2022;24(3):510
Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications (vol 23, pg 952, 2021)
Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samen E; Carlsten M; Holmin S; Tran TA
Book chapter: HANDBOOK OF NUCLEAR MEDICINE AND MOLECULAR IMAGING FOR PHYSICISTS. 2022;p. 1-11
Principles behind Radiopharmacy
Tran TA; Samén E
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:S132-S133
High yield GMP production of [¹⁸F]FE-PE2I, a radiotracer for in vivo PET imaging the dopamine transporter
Moein MM; Dahl K; Meijer E; Ferrat M; Tegnebratt T; Saliba P; Norman F; Samen E; Steiger C; Savitcheva I; Tran T
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:S216-S217
Comparative in vivo biodistribution and dosimetry in non-human primate of the fibroblast activation protein radiotracers [⁶⁸Ga]Ga-FAPI-04, [⁶⁸Ga]Ga-FAPI-46 and [¹⁸F]FAPI-74
Thuy T; Bolin M; Dahl K; Johnstrom P; Mitran B; Siikanen J; Schou M
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:S197-S198
Preparation and cGMP-compliant production of the bombesin analogue [⁶⁸Ga]Ga-NOTA-RM26 for first-in-human clinical study of gastrin-releasing peptide receptor expression in prostate cancer
Jussing E; Moein MM; Tegnebratt T; Semetaite V; Liepins E; Tzortzakakis A; Axelsson R; Orlova A; Thuy T
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2022;108:S122-S123
Automated radiolabeling of [⁶⁸Ga]Ga-DOTATOC using the iMiDEV™ automated microfluidic radiosynthesizer
Chandrashekara HK; Thuy T; Jussing E; Tanguy L; Langstrom B; Le Meunier L; Halldin C; Nag S
Review: JOURNAL OF CHROMATOGRAPHY A. 2020;1632:461611
Application of chiral chromatography in radiopharmaceutical fields: A review
Moein MM; Tran TA
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2019;46(SUPPL 1):S38-S39
Cyclotron Production of ⁶⁸Ga Using Enriched ⁶⁸Zn Foils
Siikanen J; Jussing E; Milton S; Steiger C; Ulin J; Tran T; Samen E
Conference publication: EUROPEAN HEART JOURNAL. 2019;40:674
Zirconium-89 labelled probe for molecular imaging of inflammation in experimental atherosclerosis
Ahmed M; Tegnebratt T; Tran T; Damberg P; Bone D; Lu L; Gistera A; Tarnawski L; Hedin U; Eriksson P; Holmin S; Gustafsson B; Caidahl K
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2019;62:S551-S552
Optimization of ⁸⁹Zr-based radiotracers for long-term in vivo cell tracking with PET imaging
Jonsson I; Jussing E; Zhang X-M; Lu L; Samen E; Harris R; Holmin S; Thuy T
Conference publication: 2016;:1-4
An Attenuation Method for Reducing Count Rate Losses in Preclinical PET During Intratherapeutic Imaging
Mellhammar E; Dahlbom M; Evans-Axelsson S; Axelsson J; Tran T; Strand S-E
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2015;16(12):30309-30320
Human Anti-Oxidation Protein A1M-A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy
Ahlstedt J; Tran TA; Strand S-E; Gram M; Akerstrom B
Conference publication: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS. 2015;58:S24
¹³⁵La for Auger-based therapy: preparation, imaging and emissions
Fonslet J; Tran TA; Lee BQ; Siikanen J; Larsson E; Kibedi T; Stuchbery AE; Elema DR; Severin GW
Conference publication: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2015;36:S115
Targeting human kallikrein 2 with 11B6 antibodies for radionuclide imaging and the treatment of prostate cancer
Tran TA; Timmermand OV; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2015;56(3)
Radioimmunoimaging and Radioimmunotherapy of Prostate Cancer. Preclinical evaluation of kallikrein related peptidase 2 targeting
Timmermand OV; Thuy T; Axelsson J; Elgqvist J; Ulmert D; Strand S-E
Conference publication: 2014;:1-3
Effects of High Photon Fluence Rate from Therapeutic Radionuclides on Preclinical and Clinical PET Systems
Dahlbom M; Mellhammar E; Axelsson J; Tran T; Strand S-E
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;41:S412
Cerenkov Luminescence Imaging for Intratherapy Activity Monitoring in Pre-clinical Radionuclide Therapy
Axelsson J; Vilhelmsson-Timmermand O; Tran TA; Strand S
Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;41:S280
Therapeutic Efficacy of 177Lu-labeled h11B6 in Prostate Cancer Xenografts
Timmermand OV; Elggvist J; Akesson A; Strand S; Tran TA
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55
In vivo evaluation of the radiolabeled ICAM-1 monoclonal antibody R6.5 in a prostate cancer mouse model
Axelsson SE; Trbom A; Jansson B; Timmermand OV; Tran T; Bjartell A; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55
Radiation sensitivity of prostate cancer cell lines for 177Lu, 111In, or photon irradiation
Elgqvist J; Claesson K; Larsson E; Oredsson S; Thuy T; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55
Combining optical Cherenkov luminescence imaging and SPECT for intratherapy dosimetry in preclinical radionuclide therapy
Axelsson J; Timmermand OV; Mellhammar E; Thuy T; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55
SPECT/CT imaging of the human kallikrein-2 (hK2) expression in prostate cancer using the humanized monoclonal antibody h11B6
Tran T; Elgqvist J; Strand S-E
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2014;55
In vivo evaluation of 177Lu-labeled h11B6, a humanized antibody for hK2 targeting in prostate cancer
Timmermand OV; Larsson E; Strand S-E; Thuy T
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2013;54
68Ga-labeled superparamagnetic nanoparticles for multiple PET/MR/Cherenkov luminescence imaging of sentinel nodes
Madru R; Axelsson J; Tran T; Bibic A; Ingvar C; Stahlberg F; Knutsson L; Strand S-E
Conference publication: AIP CONFERENCE PROCEEDINGS. 2012;1509(1):206-210
A peristaltic pump driven 89Zr separation module
Siikanen J; Peterson M; Tran TA; Roos P; Ohlsson T; Sandell A
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2012;53
Targeting the human kallikrein-2 (hK2) expression in prostate cancer using 111In-labelled monoclonal antibody 11B6
Thuy T; Timmermand OV; Axelsson SE; Pettersson K; Bjartell A; Lilja H; Ulmert D; Strand S-E
Editorial comment: ZDRAVNIŠKI VESTNIK. 2011;80(12):969-970
Imaging of Brain Prion Protein Amyloid in Patients with Gertstmann-Straussler-Scheinker Disease
Tran TA; Kirik D
Conference publication: JOURNAL OF NUCLEAR MEDICINE. 2011;52
Labeling proteins with ⁸⁹Zr separated from large yttrium bulks
Siikanen J; Ohlsson T; Sandell A; Strand S-E; Thuy T
Preprint: MEDRXIV.
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial
Altena R; Tran TA; Kjällquist U; Karlsson M; Siikanen J; Jussing E; Tzortzakakis A; Jonmarker O; Axelsson R; Bergh J
Visa fler

Forskningsbidrag

Antibody-based TROP-2 targeted radiopharmaceuticals for improved theranostics of metastatic solid cancers
Swedish Research Council
1 January 2024 - 31 December 2027
Development of radiopharmaceutical therapy for neuroblastoma in children
Swedish Research Council
1 December 2023 - 30 November 2026
Tran, Thuy Amanda – Development of radiotheranostics targeting TROP2 expression in triple negative breast cancer
Swedish Cancer Society
1 January 2023
Molekylära och bildgivande tekniker för kardiovaskulär riskbedömning
Swedish Heart-Lung Foundation
1 January 2021 - 31 December 2021
Klinisk implementering av förbättrade PSMA-baserade radiofarmaka för diagnostik och behandling av avancerade prostatacancer.
Region Stockholm
1 January 2019 - 31 December 2019
Cell therapy in oncology using Interventional nuclear medicine
Swedish Research Council
1 January 2018 - 31 December 2020

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI